Hirota T, Eguchi S, Ieiri I. Impact of genetic polymorphisms in CYP2C9 andCYP2C19 on the pharmacokinetics of clinically used drugs. Drug MetabPharmacokinet. 2013;28(1):28-37.
Scott SA, Sangkuhl K, Shuldiner AR, Hulot JS, Thorn CF, Altman RB, Klein TE.PharmGKB summary: very important pharmacogene information for cytochrome P450,family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics. 2012Feb;22(2):159-65. doi: 10.1097/FPC.0b013e32834d4962.
Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE,Sabatine MS, Johnson JA, Shuldiner AR; Clinical Pharmacogenetics ImplementationConsortium. Clinical Pharmacogenetics Implementation Consortium guidelines forCYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105.
Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; Writing Committee Members, Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D,O'Gara PT, Stein CM. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA"boxed warning": a report of the American College of Cardiology Foundation TaskForce on Clinical Expert Consensus Documents and the American Heart Association. Circulation. 2010 Aug 3;122(5):537-57. doi: 10.1161/CIR.0b013e3181ee08ed.
Uppugunduri CR, Daali Y, Desmeules J, Dayer P, Krajinovic M, Ansari M.Transcriptional regulation of CYP2C19 and its role in altered enzyme activity.Curr Drug Metab. 2012 Oct;13(8):1196-204. Review.
Contributor
MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register
: Vivi Li
You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
OK
Confirm
Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?